Long-term topotecan therapy in recurrent or persistent ovarian cancer

Background: The objective of this study was to evaluate feasibility, safety and clinical outcome of long-term therapy with topotecan (Hycamtin) in recurrent or persistent ovarian cancer. Patients and methods: A retrospective chart review was conducted on all patients treated with topotecan (TPT) at the Department of Obstetrics and Gynecology, University of Bari, Italy between 1999 and 2007. Pertinent clinicopathologic information, response and toxicity following treatment with TPT were collected. TPT was given at a dosage ranging between 1.5 and 1.0 mg/m2 every three to four weeks. All patients were evaluated for toxicity acording to the CTC and response according to the RECIST response criteria. Time to progression (TTP) was calculated from initiation of TPT treatment and start of the next chemotherapy regimen. Results: A total of 30 patients received TPT for at least eight cycles for recurrent ovarian (22), fallopian tube (3) or primary peritoneal carcinoma (5). A total of 432 cycles of chemotherapy were given, with an average of 14.4 cycles per patient (range 8-22). Dose reduction was necessary in 20 patients (66%). About half of the patients required blood transfusions and growth factors. Non hematologic toxicity was mild and manageable. Responses were observed in 16/30 patients (53%), the remaining having SD. Median time to treatment progression was 28 months (range 9-88). Conclusion: Long-term treatment with topotecan in recurrent/persistent ovarian cancer is feasible with limited evidence of cumulative toxicity. The results of this retrospective analysis suggest a potential role for late response and survival benefit for those patients without disease progression who continue topotecan therapy beyond six cycles of treatment.

Recurrent ovarian cancer; Topotecan; Ovarian carcinoma

[1] Wing P.A., Tong T., Bolden S.: “Cancer statistics”. CA Cancer J. Clin., 1995, 45, 8.

[2] Harries M., Gore M.: “Chemotherapy for epithelial ovarian cancer. Treatment of recurrent disease”. Lancet Oncol., 2002, 3, 537.

[3] Markman M., Bookman M.A.: “Second-line treatment of ovarian cancer”. Oncologist, 2000, 5, 26.

[4] Mobus V., Kieback D.G., Kaubitzsch S.K.: “Duration of chemotherapy with topotecan influences survival in recurent ovarian cancer: a meta-analysis”. Anticancer Res., 2007, 27, 1581.

[5] International Federation of Gynecology and Obstetrics: “Changes in definitions of clinical staging for carcinoma of the cervix and ovary”. Am. J. Obstet. Gynecol., 1987, 156, 263.

[6] Therasse P., Arbuck Sg., Eisenhauer E.A. et al.: “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada”. J. Natl. Cancer Inst., 2000, 92, 205.

[7] Ozols R.F.: “Maintenance therapy in advanced ovarian cancer:progression-free survival and clinical benefit”. J. Clin. Oncol., 2003, 21, 2451.

[8] Markman M., Liu P.Y., Wilczynski S. et al.: “Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with dvanced ovarian cancer after complete response to platiunum and paclitaxel based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial”. J. Clin. Oncol., 203, 21, 2460.

[9] Spriggs D.: “Duration of therapy for ovarian cancer: how long is enough?. Cancer Invest., 2004, 1 (suppl.), 44.

[10] Markman M., Markman J., Webster K. et al.: “Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implication for patient management and clinical trial design”. J. Clin. Oncol., 2004,22, 3120.

[11] Spriggs D.: “Optimal sequencing in the treatment of recurrent ovarian cancer”. Gynecol. Oncol., 2003, 90 (3 suppl. 1), S39.

[12] Andreopolou E., Gaiotti D., Kim E. et al.: “Pegylated liposomal doxorubicin HCL (PLD; Caelys/Doxil): experience with longterm maintenance in responding patiens with recurrent epithelial ovarian cancer”. Ann. Oncol., 2007, 18, 716.